RIGEL PHARMACEUTICALS INC 8-K

What Happened Rigel Pharmaceuticals announced on June 17, 2026 (Form 8-K) that the License Agreement it previously disclosed on May 12, 2026 became effective and the transactions closed. The Company obtained exclusive, global rights to develop, manufacture and commercialize VEPPANU™ (vepdegestrant) and related products from Arvinas, Inc., Arvinas Operations, Inc., Arvinas Estrogen Receptor, Inc. and Pfizer Inc.

Key Details

• The filing is Item 2.01: Completion of Acquisition or Disposition of Assets.
• The License Agreement became effective after early termination of the Hart-Scott-Rodino waiting period and satisfaction of other closing conditions.
• Rigel paid a one-time upfront cash payment of $70.0 million to the licensors.
• Initial disclosure of the License Agreement was made in a Form 8-K filed May 12, 2026.

Why It Matters This transaction gives Rigel exclusive global rights to a therapeutic asset (VEPPANU/vepdegestrant), adding to its product portfolio and control over development and commercialization decisions. The $70.0 million upfront payment is a material cash outflow that investors should consider when assessing the company’s near-term cash position and capital allocation. The completed deal may affect future revenue potential if Rigel successfully develops and commercializes the product.